Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2010
06/10/2010US20100143335 Treating atherosclerosis
06/10/2010US20100143334 T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
06/10/2010US20100143333 Method of treating diabetes
06/10/2010US20100143332 Combination therapy for proliferative disorders
06/10/2010US20100143331 Method for mixing powders
06/10/2010US20100143330 Methods of treating disorders associated with fat storage
06/10/2010US20100143329 Reimmunization and antibody design
06/10/2010US20100143328 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
06/10/2010US20100143298 Colloidal metal compositions and methods
06/10/2010US20100143296 Podophyllotoxin inhibitors of topoisomerase ii
06/10/2010US20100143295 Quinazoline inhibitors of egfr tyrosine kinase
06/10/2010US20100143294 Antagonists of il-6 to prevent or treat thrombosis
06/10/2010US20100143290 Monoclonal antibodies to human thymidine kinase to treat cancer
06/10/2010US20100143266 Methods for reducing allergies caused by environmental allergens
06/10/2010US20100143257 Prevention of Cancers by Immunization
06/10/2010US20100143246 Interleukin 17 Receptor-Like Protein
06/10/2010US20100143245 Uses of monoclonal antibody 8h9
06/10/2010US20100143244 Monoclonal antibodies to human thymidine kinase to treat cancer
06/10/2010US20100143243 Frozen compositions and methods for piercing a substrate
06/10/2010DE4419264B4 Antigen, um Menschen und Tieren eine schützende Immunität gegen Wurminfektionen zu verleihen To confer antigen humans and animals protective immunity against worm infections
06/10/2010DE102008060614A1 Verfahren zur Herstellung einer Inhalationsatmosphäre für die Allergenprovokation Process for the preparation of an inhalation atmosphere for allergen challenge
06/10/2010CA2746511A1 Compositions and methods for the treatment and prevention of lens fibrotic diseases
06/10/2010CA2745923A1 Sparc binding scfvs
06/10/2010CA2745618A1 Anti-ferroportin 1 monoclonal antibodies and uses thereof
06/10/2010CA2745603A1 Use of phenol soluble modulins for the development of vaccines
06/10/2010CA2745598A1 Fully human influenza m2 specific antibodies
06/10/2010CA2745473A1 Anti-cobra toxin antibody fragments and method of producing a vhh library
06/10/2010CA2745470A1 Modified protozoan expressing at least two variable surface proteins (vsp), a vaccine comprising it and procedures, uses, and methods thereof
06/10/2010CA2745408A1 Wdrpuh epitope peptides and vaccines containing the same
06/10/2010CA2745288A1 Antibodies for guanylyl cyclase receptors
06/10/2010CA2745271A1 Dual variable domain immunoglobulins and uses thereof
06/10/2010CA2745205A1 Glutamyl trna synthetase (gts) fragments
06/10/2010CA2745111A1 Modulation of olfml-3 mediated angiogenesis
06/10/2010CA2744960A1 Il-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage
06/10/2010CA2744750A1 Bovine viral diarrhea virus with a modified erns protein
06/10/2010CA2744663A1 Vaccine
06/10/2010CA2744065A1 Process for the modulation of the antagonistic activity of a monoclonal antibody
06/10/2010CA2737403A1 Process for production of vaccines
06/10/2010CA2710264A1 Anti-nr10 antibody and use thereof
06/09/2010EP2194144A1 Roles for dual Endothelin-1/Angiotensin II receptor (DEAR) in hypertension and angiogenesis
06/09/2010EP2194132A1 Vaccine composition comprising a mixture of a recombinant protein containing a C-terminal p19 fragment of the MSP-1 protein from plasmodium falciparum and another recombinant p19 protein from a plasmodium homologous to P. falciparum
06/09/2010EP2194130A1 Cytokine ZCYTO18
06/09/2010EP2194067A2 Antibodies to insulin-like growth factor I receptor (IGF-IR)
06/09/2010EP2194066A1 Modified antibody constant region
06/09/2010EP2193810A1 Meningococcal conjugate vaccination
06/09/2010EP2193805A1 Immunosuppression weaning agent comprising tumor cell and antitumor agent using the same
06/09/2010EP2193804A2 Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
06/09/2010EP2193803A1 Nucleic acids encoding immunoglobins carrying gp100 and TRP2 epitopes
06/09/2010EP2193802A2 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
06/09/2010EP2193801A2 Caspase-8 and inflammation, infection and wound healing
06/09/2010EP2193790A1 IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage
06/09/2010EP2193147A1 Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof
06/09/2010EP2193143A2 Compositions of humanized notch fusion proteins and methods of treatment
06/09/2010EP2192955A1 A modulator of nrg1 for treatment of respiratory disorders
06/09/2010EP2192922A2 Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
06/09/2010EP2192921A1 Intraoperative trifunctional antibody administration for prophylaxis of intraperitoneal tumor cell dissemination
06/09/2010EP2192919A1 Methods of inhibiting tumor growth using beta 5 integrin antagonists
06/09/2010EP2192918A1 Hiv env proteins with modifications in the v3 loop
06/09/2010EP2192917A1 Method for producing viral vaccines
06/09/2010EP2192914A1 Polymeric linkers containing pyridyl disulfide moieties
06/09/2010EP1804835B1 Multimeric constructs
06/09/2010EP1737490B1 Methods of treating atherosclerosis
06/09/2010EP1572744B1 Immunoglobulin variants and uses thereof
06/09/2010EP1558649B1 Peptid modulating caspase activation
06/09/2010EP1385864B1 Anti-VEGF-2 antibodies
06/09/2010EP0951295B1 Compositions for use in inhibiting of alpha-v-beta3 mediated angiogenesis
06/09/2010CN1994465B CCR5 autogenous polypeptide vaccine and preparation method thereof
06/09/2010CN1981043B Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
06/09/2010CN1922324B Bacterial virulence factors and uses thereof
06/09/2010CN1874784B Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
06/09/2010CN1517437B Vaccine for specificity treating tumour or endocellular infection and application
06/09/2010CN101730546A Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
06/09/2010CN101730545A Compounds and methods for the treatment of renal disease
06/09/2010CN101730544A Adaptation of pitman moore strain of rabies virus to primary chick embryo fibroblast cell cultures
06/09/2010CN101730543A inactivated staphylococcal whole-cell vaccine
06/09/2010CN101730542A Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
06/09/2010CN101730541A Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
06/09/2010CN101724606A Porcine circoviruses, vaccines and diagnostic reagents
06/09/2010CN101724605A Foot-and-mouth disease virus (FMDV) resistant monoclonal antibody and identified epitope and application thereof
06/09/2010CN101724085A Method for purifying capsular polysaccharide
06/09/2010CN101724075A Remodeling and glycoconjugation of peptides
06/09/2010CN101724074A Humanized chimeric antibody of angiostatin receptor beta subunit, preparation thereof and application thereof
06/09/2010CN101724072A Sequence and application thereof of anti-tumor monoclonal antibody
06/09/2010CN101724070A humanized anti-ngf antibodies
06/09/2010CN101724020A Immunological contraception target universal for mammals and specific antibody thereof
06/09/2010CN101724011A Preparation method and application of tumor tissue complete antigen
06/09/2010CN101724010A Preparation method and application of tumor tissue complete antigen
06/09/2010CN101721702A Formulation of human antibodies for treating TNF-alpha associated disorders
06/09/2010CN101721701A Crystallization of antibodies or fragments thereof
06/09/2010CN101721700A Lyophilized preparation of anti-human Her2 antibody
06/09/2010CN101721699A Application of VEGF receptor fusion protein in preparing medicament for treating inflammatory reaction accompanying increase of VEGF
06/09/2010CN101721698A Foot-and-mouth disease resistant vaccine composition and preparation and application thereof
06/09/2010CN101721697A Anti-cancer and anti-infectious disease compositions and methods for using same
06/09/2010CN101721696A Trivalent oil emulsion inactivated vaccine for 4 type, 5 type and 13 type serum of haemophilus parasuis
06/09/2010CN101721695A Novel trivalent inactivated vaccine for swine streptococcosis
06/09/2010CN101721694A Hircine primary atypical pneumonia combined inactivated vaccine and preparation method thereof
06/09/2010CN101721693A Improved recombinant bacillus calmetter Guerin (BCG)
06/09/2010CN101721692A Application of nonpathogenic edwarsiella tarda
06/09/2010CN101721362A Antibody-containing solution pharmaceuticals
06/09/2010CN101280316B Therapeutic vaccine for human cervical carcinoma
1 ... 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 ... 1823